GlassScriptPhysician profile
Shashitha Gavini
NPI 1376074179
$5,858.69
in general payments reported to CMS, 2019-2025
33 companies · $2,744 in 2025
The $2,744 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.35 · 2020: $38.84 · 2021: $166 · 2022: $395 · 2023: $1,059 · 2024: $1,372 · 2025: $2,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,175.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $992.26 | 2022-2025 | Repatha, Repatha |
| Abbott Laboratories | $941.15 | 2022-2025 | Cardiomems, Aveir, Jot Dx |
| Kestra Medical Technology Services, INC. | $804.24 | 2025 | Assure Wcd |
| Medtronic, INC. | $762.66 | 2023-2025 | Corevalve Evolut R, Symplicity G3, Linq II |
| Abiomed | $277.42 | 2024-2025 | Impella |
| Pfizer INC. | $171.58 | 2022-2025 | |
| Edwards Lifesciences Corporation | $162.27 | 2022-2025 | Evoque |
| Bard Peripheral Vascular, INC. | $159.82 | 2025 | Venovo |
| Endologix LLC | $148.27 | 2025 | Torus Stent Graft System, Endocross Device |
| Astrazeneca Pharmaceuticals LP | $144.60 | 2020-2025 | Farxiga |
| Cardiovascular Systems INC. | $139.50 | 2021 | |
| Penumbra, INC. | $136.71 | 2023 | Indigo System |
| Shockwave Medical, INC | $125.45 | 2025 | |
| Itamar Medical INC | $114.05 | 2023-2024 | Watchpatone |
| Daiichi Sankyo INC. | $106.09 | 2024 | Injectafer |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $99.07 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $85.57 | 2020-2025 | Camzyos, Eliquis |
| Otsuka America Pharmaceutical, INC. | $83.35 | 2019 | |
| Inspire Medical Systems, INC. | $55.41 | 2024-2025 | Inspire |
| Cardiac Dimensions, INC. | $50.82 | 2025 | |
| Merck Sharp & Dohme LLC | $44.98 | 2023 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $42.57 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.32 | 2023-2024 | Lifevest |
| Cardiva Medical, INC. | $23.12 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Kiniksa Pharmaceuticals International, Plc | $20.88 | 2024 | Arcalyst |
| Atricure, INC. | $20.28 | 2024 | |
| Janssen Pharmaceuticals, INC | $17.79 | 2024 | Xarelto |
| Esperion Therapeutics, INC. | $17.05 | 2025 | Nexletol |
| Kiniksa Pharmaceuticals, LTD. | $15.11 | 2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $14.80 | 2024 | |
| Boston Scientific Corporation | $14.77 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $14.03 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.70 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shashitha Gavini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.